<?xml version='1.0' encoding='utf-8'?>
<document id="30324316"><sentence text="Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials."><entity charOffset="50-60" id="DDI-PubMed.30324316.s1.e0" text="Fimasartan" /><entity charOffset="62-72" id="DDI-PubMed.30324316.s1.e1" text="Amlodipine" /><entity charOffset="78-97" id="DDI-PubMed.30324316.s1.e2" text="Hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.30324316.s1.e0" e2="DDI-PubMed.30324316.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30324316.s1.e0" e2="DDI-PubMed.30324316.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s1.e0" e2="DDI-PubMed.30324316.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30324316.s1.e1" e2="DDI-PubMed.30324316.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s1.e1" e2="DDI-PubMed.30324316.s1.e2" /></sentence><sentence text="To build a physiologically based pharmacokinetic (PBPK) model for fimasartan, amlodipine, and hydrochlorothiazide, and to investigate the drug-drug interaction (DDI) potentials"><entity charOffset="66-76" id="DDI-PubMed.30324316.s2.e0" text="fimasartan" /><entity charOffset="78-88" id="DDI-PubMed.30324316.s2.e1" text="amlodipine" /><entity charOffset="94-113" id="DDI-PubMed.30324316.s2.e2" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.30324316.s2.e0" e2="DDI-PubMed.30324316.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30324316.s2.e0" e2="DDI-PubMed.30324316.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s2.e0" e2="DDI-PubMed.30324316.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30324316.s2.e1" e2="DDI-PubMed.30324316.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s2.e1" e2="DDI-PubMed.30324316.s2.e2" /></sentence><sentence text="" /><sentence text="The PBPK model of each drug was developed using Simcyp software (Version 15" /><sentence text="0), based on the information obtained from literature sources and in vitro studies" /><sentence text=" The predictive performance of the model was assessed by comparing the predicted PK profiles and parameters with the observed data collected from healthy subjects after multiple oral doses of fimasartan, amlodipine, and hydrochlorothiazide"><entity charOffset="192-202" id="DDI-PubMed.30324316.s6.e0" text="fimasartan" /><entity charOffset="204-214" id="DDI-PubMed.30324316.s6.e1" text="amlodipine" /><entity charOffset="220-239" id="DDI-PubMed.30324316.s6.e2" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.30324316.s6.e0" e2="DDI-PubMed.30324316.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30324316.s6.e0" e2="DDI-PubMed.30324316.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s6.e0" e2="DDI-PubMed.30324316.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30324316.s6.e1" e2="DDI-PubMed.30324316.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s6.e1" e2="DDI-PubMed.30324316.s6.e2" /></sentence><sentence text=" The DDI potentials after co-administration of three drugs were simulated using the final model" /><sentence text="" /><sentence text="The predicted-to-observed ratios of all the pharmacokinetic parameters met the acceptance criterion" /><sentence text=" The PBPK model predicted no significant DDI when fimasartan was co-administered with amlodipine or hydrochlorothiazide, which is consistent with the observed clinical data"><entity charOffset="50-60" id="DDI-PubMed.30324316.s10.e0" text="fimasartan" /><entity charOffset="86-96" id="DDI-PubMed.30324316.s10.e1" text="amlodipine" /><entity charOffset="100-119" id="DDI-PubMed.30324316.s10.e2" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.30324316.s10.e0" e2="DDI-PubMed.30324316.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30324316.s10.e0" e2="DDI-PubMed.30324316.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s10.e0" e2="DDI-PubMed.30324316.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30324316.s10.e1" e2="DDI-PubMed.30324316.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s10.e1" e2="DDI-PubMed.30324316.s10.e2" /></sentence><sentence text=" In the simulation of DDI at steady-state after co-administration of three drugs, the model predicted that fimasartan exposure would be increased by ~24" /><sentence text="5%, while no changes were expected for the exposures of amlodipine and hydrochlorothiazide"><entity charOffset="56-66" id="DDI-PubMed.30324316.s12.e0" text="amlodipine" /><entity charOffset="71-90" id="DDI-PubMed.30324316.s12.e1" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.30324316.s12.e0" e2="DDI-PubMed.30324316.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30324316.s12.e0" e2="DDI-PubMed.30324316.s12.e1" /></sentence><sentence text="" /><sentence text="The developed PBPK model adequately predicted the pharmacokinetics of fimasartan, amlodipine, and hydrochlorothiazide, suggesting that the model can be used to further investigate the DDI potential of each drug"><entity charOffset="70-80" id="DDI-PubMed.30324316.s14.e0" text="fimasartan" /><entity charOffset="82-92" id="DDI-PubMed.30324316.s14.e1" text="amlodipine" /><entity charOffset="98-117" id="DDI-PubMed.30324316.s14.e2" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.30324316.s14.e0" e2="DDI-PubMed.30324316.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30324316.s14.e0" e2="DDI-PubMed.30324316.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s14.e0" e2="DDI-PubMed.30324316.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30324316.s14.e1" e2="DDI-PubMed.30324316.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30324316.s14.e1" e2="DDI-PubMed.30324316.s14.e2" /></sentence><sentence text="" /></document>